UHHS has been acquired by Vitapart
The shareholders of Vitapart have sold the company to UHHS.
Founded in 1989 in São Paulo, UHHS is one of the most renowned hemotherapy and cell therapy centers in Brazil. Located at Hospital Samaritano, UHHS performs more than 1,200 blood transfusions per month and is a reference in highly complex procedures, in addition to developing numerous scientific research and new medical protocols.
Founded in 2017, Vitapart was created to lead the consolidation process in the blood therapy sector in Brazil. Headquartered in Belo Horizonte, the company has already acquired numerous companies in the sector and is present in all regions of the country. The acquisition of UHHS marked Vitapart’s entry into the city of São Paulo and is part of the expansion plan in the region. In addition, the group will benefit from UHHS’s medical expertise. Vitapart is a portfolio company of the private equity fund Crescera.
One of Oaklins’ teams in Brazil acted as the exclusive financial advisor in the preparation of the sale process and due diligence, shareholders agreement, and assisted them until closing.
Natan Lessa Goyatá
CEO, Vitapart
Talk to the deal team
Priscila Cardanha Rosas
Oaklins Fortezza Partners
Related deals
SHS has sold Spiegelberg to Luciole Medical AG
SHS and a minority co-shareholder have sold Spiegelberg GmbH to Luciole Medical AG.
Learn moreZephyr Group has acquired PK OEM Parts
Zephyr Group has acquired PK OEM Parts. With the entry of PK OEM Parts, Zephyr Group aims to achieve a consolidated turnover of approximately US$65 million in 2023. The acquisition will allow an increase in the services and product range offered to customers by leveraging the group’s know-how and logistical capabilities. Furthermore, the acquisition represents a step forward in the growth and consolidation strategy that Zephyr Group started in 2018 with the acquisition of Spanish competitor SKV.
Learn moreBaird Capital invests in Freemarket
Baird Capital has completed a growth capital investment in Freemarket. The investment supports Freemarket’s continuing fast growth and international expansion, as well as providing a partial cash-out to existing shareholders.
Learn more